홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

4-Methylmorpholine → Leucinamide

HRID 850879
인쇄

반응식

HRID 850879 반응식
C(OC(CCC(N[C@H](C(N[C@H](C([NH:37][C@H:38]([C:47]([NH:49][C@H](C(N[C@H](C(O)=O)CC(C)C)=O)C(C)(C)C)=[O:48])[CH2:39][C:40]1[CH:45]=CC=C[C:41]=1C)=O)CCC(=O)OC(C)(C)C)=O)CC(=O)OC(C)(C)C)=O)=O)(C)(C)C.CN1CCOCC1.ClC(OCC(C)C)=O.FC(F)(F)C(O)=O.C(C(B1OC(C)(C)C(C)(C)O1)N)CC>CN(C)C=O.ClCCl>[NH2:37][C@H:38]([C:47]([NH2:49])=[O:48])[CH2:39][CH:40]([CH3:45])[CH3:41]
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

7

반응물 4

HCID 79724-MethylmorpholineHCID 62365Isobutyl chloroformateHCID 19364641alpha-(RS)-propyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-methylamine trifluoroacetateHCID 22942121N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-alpha-aspartyl]-O-tert-butyl-L-alpha-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucine

생성물 1

HCID 69640
Leucinamide

시약·촉매·용매 2

HCID 6228Dimethylformamide용매HCID 6344Dichloromethane용매

반응 조건

온도
-15 °C

실험 절차

0.2 g (0.218 mmol) of N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-α-aspartyl]-O-tert-butyl-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucine was dissolved in 2 ml of dimethylformamide and 6 ml of dichloromethane. 0.12 ml (1.1 mmol) of N-methylmorpholine was added and the solution was cooled to -15° C. under a nitrogen atmosphere. 40 mg (0.31 mmol) of isobutyl chloroformate were added and the solution was stirred for 10 minutes at -15° C. 0.14 g (0.44 mmol) of α-(RS)-propyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-methylamine trifluoroacetate was added and the mixture was stirred at room temperature for 66 hours. After evaporation the residue was partitioned between ethyl acetate and 2M hydrochloric acid. The organic layer was washed with 2M hydrochloric acid, water and saturated sodium chloride solution and then dried over anhydrous sodium sulphate. After evaporation there was obtained 0.17 g of N2-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-α-aspartyl]-O-tert-butyl-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-N1-N1(RS)-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-L-leucinamide in the form of a solid; NMR (DMSO, 400 MHz) δ: 0.75-0.9 (m,17H), 1.01-1.08 (m,6H), 1.15-1.25 (m,1H), 1.35 9s,36H), 1.4-1.7 (m,4H), 1.75-1.8 (m,1H), 2.05-2.15 (m,2H), 2.23 (s,3H), 2.29-2.41 (m,6H), 2.55-2.6 (m,1H), 2.7-2.74 (m,1H), 2.95-3.05 (m,1H), 4.15-4.25 (m,3H), 4.48-4.55 (m,1H), 4.6-4.7 (m,1H), 7.05-7.11 (m,4H), 7.7-7.81 (m,2H), 8.05-8.12 (m,2H), 8.15-8.25 (m,2H).

후처리

  1. stirringthe mixture was stirred at room temperature for 66 hours
  2. customAfter evaporation the residue
  3. customwas partitioned between ethyl acetate and 2M hydrochloric acid
  4. washThe organic layer was washed with 2M hydrochloric acid, water and saturated sodium chloride solution
  5. dry with materialdried over anhydrous sodium sulphate
  6. customAfter evaporation

출처 및 근거

ORD 기록
ord-806193b3f8944e03904cc875d100da43
출처 데이터셋
uspto-grants-2000_01
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US06018020

반응 노트

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트